Tag Archive for: biotech

Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma

/in

Berlin, Germany, 29th February 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce that it has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to undertake a Phase 1 clinical trial (CITADEL-123) of 123I-ATT001, its Iodine-123 labelled PARP […]

Read more

STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at ESMO Targeted Anticancer Therapies Congress

/in

Data demonstrates pharmacological inhibition of METTL1 inhibits tumour growth and reduces tRNA methylation and stability of tRNAs 22 February 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced that Alexandra Sapetschnig, Group Leader at STORM, will […]

Read more

Poolbeg Pharma plc – Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

/in

Former Amryt team’s arrival supports increasing focus upon Rare and Orphan Diseases 12 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces that independent research[i] [ii] conducted on behalf of Poolbeg confirms a >$10 billion market opportunity […]

Read more

Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead Dialysis Product H-Guard®

/in

First patients treated with H-Guard® at the National Institute for Health and Care Research Manchester Clinical Research Facility MHRA approves continuation of Invizius’s first-in-human clinical study following a prearranged two-patient safety and performance review Study is investigating safety and tolerability of H-Guard®, a second generation complement regulator, to address serious immune system-driven complications of dialysis […]

Read more